Clinical features and prognostic factors of small cell lung cancer: A retrospective study in 148 patients

Abstract

To better understand the outcomes of small cell lung cancer (SCLC), we examined the clinical features and prognostic factors of SCLC in this study. A total of 148 patients who were diagnosed as having SCLC between January 2009 and December 2013 in Cancer Center of Union Hospital, Wuhan, China, were enrolled and their clinical features and prognostic factors were retrospectively analyzed. Log-rank test and Cox regression model were employed for analysis of prognostic factors. The 1- and 2-year overall survival (OS) rates were 59.7% and 25.7%, respectively, for limited disease (LD) patients whose median survival time (MST) was 16 months. The 1- and 2-year OS rates were 29.5% and 5.3%, respectively, for extensive disease (ED) patients whose MST was 10 months. The univariate analysis and multivariate analysis revealed that age, tumor stage, serum CEA and Ki-67 antigen were significantly correlated to the outcomes of SCLC, and they were significant prognostic factors for SCLC.

Keywords

small cell lung cancer / survival rate / prognosis factor

References

[1] JemalA, BrayF, CenterMM, et al. . Global cancer statistics. CA Cancer J Clin, 2011, 61(2): 69-90 PMID: 21296855

[2] SorensenM, FelipE E G W Group. Small-cell lung cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol, 2009, 20: 71-72 PMID: 19454469

[3] KurupA, HannaNH. Treatment of small cell lung cancer. Crit Rev Oncol Hematol, 2004, 52(2): 117-126 PMID: 15501076

[4] PengH. Study on the epidemiology characteristics and prognosis of hospitalized lung cancer patients, 2010, Shanghai, Fudan University

[5] PuglisiM, DollyS, FariaA, et al. . Treatment options for small cell lung cancer–do we have morechoice?. Br J Cancer, 2010, 102(4): 629-638 PMID: 20104223 PMCID: 2837580

[6] EisenhauerEA, TherasseP, BogaertsJ, et al. . New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer, 2009, 45(2): 228-247 PMID: 19097774

[7] ParsonsHM, HarlanLC, StevensJL, et al. . Treatment of small cell lung cancer in academic and community settings: factors associated with receiving standard therapy and survival. Cancer J, 2014, 20(2): 97-104 PMID: 24667952 PMCID: 3999900

[8] LiuT, LiuH, LiY. Early lung cancer in the elderly: sublobar resection provides equivalent long-term survival in comparison with lobectomy. Contemp Oncol (Pozn), 2014, 18(2): 111-115

[9] SinhaN, NiaziM, Diaz-FuentesG, et al. . An innocent appearing subcutaneous nodule diagnoses a small cell lung cancer in a never-smoker female. Case Rep Oncol Med, 2014, 2014: 268404 PMID: 24744927 PMCID: 3972869

[10] KarpathiouG, GiatromanolakiA, KoukourakisMI, et al. . Histological changes after radiation therapy in patients with lung cancer: a prospective study. Anticancer Res, 2014, 34(6): 3119-3124 PMID: 24922681

[11] PapadopoulosA, GuidaF L K, et al. . Heavy smoking and lung cancer: are women at higher risk? Result of the ICARE study. Br J Cancer, 2014, 110(5): 1385-1391 PMID: 24423926 PMCID: 3950853

[12] LiJ, DaiCH, ChenP, et al. . Survival and prognostic factors in small cell lung cancer. Med Oncol, 2010, 27(1): 73-81 PMID: 19214813

[13] Xu YJ, Zheng H, Gao W, et al. Is neoadjuvant chemotherapy mandatory for limited-disease small-cell lung cancer? Interact Cardiovasc Thorac Surg, 2014,19(6):887–893

[14] TakeiH, KondoH, MiyaokaE, et al. . Surgery for small cell lung cancer: a retrospective analysis of 243 patients from Japanese lung cancer registry in 2004. J Thorac Oncol, 2014, 9(8): 1140-1145 PMID: 25157766

[15] GoldsteinSD, YangSC. Role of surgery in small cell lung cancer. Surg Oncol Clin N Am, 2011, 20(4): 769-777 PMID: 21986271

[16] SatouchiM, KotaniY, ShibataT, et al. . Phase III study comparing amrubicin plus cisplatin with irinotecan plus cisplatin in the treatment of extensive-disease small-cell lung cancer: JCOG 0509. J Clin Oncol, 2014, 32(12): 1262-1268 PMID: 24638015

[17] ZatloukalP, CardenalF, SzczesnaA, et al. . A multicenter international randomized phase III study comparing cisplatin in combination with irinotecan or etoposide in previously untreated small-cell lung cancer patients with extensive disease. Ann Oncol, 2010, 21(9): 1810-1816 PMID: 20231298

[18] HansenO, SørensenP, HansenKH. The occurrence of hyponatremia in SCLC and the influence on prognosis: A retrospective study of 453 patients treated in a single institution in a 10-year period. Lung Cancer, 2010, 68(1): 111-114 PMID: 19535164

[19] TiseoM, ButiS, BoniL, et al. . Prognostic role of hyponatremia in 564 small cell lung cancer patients treated with topotecan. Lung Cancer, 2014, 86(1): 91-95 PMID: 25130081

[20] JeremicB, ShibamotoY, NikolicN, et al. . Role of radiation therapy in the combined-modality treatment of patients with extensive disease small-cell lung cancer: a randomized study. J Clin Oncol, 1999, 17(7): 2092-2099 PMID: 10561263

[21] LuH, FangL, WangX, et al. . A meta-analysis of randomized controlled trials comparing early and late concurrent thoracic radiotherapy with etoposide and cisplatin/ carboplatin chemotherapy for limited-disease small-cell lung cancer. Mol Clin Oncol, 2014, 2(5): 805-810 PMID: 25054049 PMCID: 4106745

[22] XiaoXG, WangSJ, HuLY, et al. . Relationship between the SER treatment period and prognosis of patients with small cell lung cancer. Asian Pac J Cancer Prev, 2014, 15(15): 6415-6419 PMID: 25124635

[23] IgawaS, GohdaK, FukuiT, et al. . Circulating tumor cells as a prognostic factor in patients with small cell lung cancer. Oncol Lett, 2014, 7(5): 1469-1473 PMID: 24765158 PMCID: 3997694

[24] LiY, ShenY, MiaoY, et al. . Co-expression of uPAR and CXCR4 promotes tumor growth and metastasis in small cell lung cancer. Int J Clin Exp Pathol, 2014, 7(7): 3771-3780 PMID: 25120753 PMCID: 4128988

[25] KangMH, GoSI, SongHN, et al. . The prognostic impact of the neutrophil-to-lymphocyte ratio in patients with small-cell lung cancer. Br J Cancer, 2014, 111(3): 452-460 PMID: 24921916 PMCID: 4119986

[26] WangX, LinL, RenX, et al. . High expression of oncoprotein DEK predicts poor prognosis of small cell lung cancer. Int J Clin Exp Pathol, 2014, 7(8): 5016-5023 PMID: 25197373 PMCID: 4152063

[27] ParkMR, ParkYH, ChoiJW, et al. . Progression-free survival: an important prognostic marker for long-term survival of small cell lung cancer. Tuberc Respir Dis (Seoul), 2014, 76(5): 218-225

[28] WangX, JiangR, LiK. Prognostic significance of pretreatment laboratory parameters in combined small-cell lung cancer. Cell Biochem Biophys, 2014, 69(3): 633-640 PMID: 24554485

[29] WarthA, CortisJ, SoltermannA, et al. . Tumour cell proliferation (Ki-67) in non-small cell lung cancer: a critical reappraisal of its prognostic role. Br J Cancer, 2014, 111(6): 1222-1229 PMID: 25051406 PMCID: 4453847

[30] ArazO, DemirciE, UcarEY, et al. . Roles of Ki-67, p53, transforming growth factor-ß and lysyl oxidase in the metastasis of lung cancer. Respirology, 2014, 19(7): 1034-1039 PMID: 24995672

[31] PelosiG, RindiG, TravisWD, et al. . Ki-67 antigen in lung neuroendocrine tumors: unraveling a role in clinical practice. J Thorac Oncol, 2014, 9(3): 273-284 PMID: 24518085